Stock-Based Compensation |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock-Based Compensation |
Equity incentive plan – summary
During 2023, the Company adopted the OneMedNet Corporation 2022 Equity Incentive Plan (the “2022 Plan”) and reserved an amount of shares of The 2022 Plan became effective immediately upon the closing of the Business Combination and replaced the Legacy ONMD equity incentive plan.
Equity incentive plan – stock options
For the three months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $ and $ thousand, respectively, on its outstanding stock options.
For the six months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $ thousand and $ thousand, respectively, on its outstanding stock options.
Equity incentive plan – restricted stock units (“RSU”)
For the three months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $ thousand and $ thousand, respectively, on its outstanding restricted stock units.
For the six months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $ thousand and $ thousand, respectively, on its outstanding restricted stock units.
|